Participant flow

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes · Source last updated 2018-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   azacitidine: Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity. lenalidomide: Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.

   id

   FG000

   title

   Lenalidomide and Azacitidine

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         37

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      Azacitidine 75mg/Lenalidomide 5mg-14 Day

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      Azacitidine 75mg/Lenalidomide 5mg-21 Day

   4. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      Azacitidine 75mg/Lenalidomide 10mg-14day

   5. achievements

      1. group Id

         FG000

         num Subjects

         37

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice